Bli medlem
Bli medlem

Du är här

2016-03-11

Bionor Pharma ASA: Bionor Pharma ASA completes extraordinary general meeting

BIONOR PHARMA ASA

STOCK EXCHANGE ANNOUNCEMENT

Bionor Pharma ASA completes extraordinary general meeting

(Oslo, Norway, 11 March 2016) Bionor Pharma ASA (OSE:BIONOR) has today
completed an Extraordinary General Meeting (EGM), which elected a new Board
of Directors according to the unanimous proposal from the Nomination
Committee announced 8 March 2016. Following the Extraordinary General
Meeting, the Board is composed as follows:

· Per Thoresen as newly elected Chairman of the Board
· Lars H. Høie as new Board Member
· Jerome B. Zeldis as re-elected Board Member
· Benedicte Fossum as re-elected Board Member
· Thomas Hofstaetter as re-elected Board Member
· Kirsten Drejer as re-elected Board Member
· Ingrid Leisner as new Board Member

Please see the attached minutes from the meeting in Norwegian and English
translation.

This information is published in accordance with the requirements of the
Continuing Obligations.

Further information
David Horn Solomon, President and CEO, +45 22 20 63 00,dhs@bionorpharma.com

Jens Krøis, CFO, +45 20 80 16 68,jk@bionorpharma.com

Jørgen Fischer Ravn, VP Investor Relations&Communications, +45 20 30 39
03,jfr@bionorpharma.com

About Bionor
Bionor Pharma is a Norwegian biopharmaceutical company focused on advancing
its proprietary therapeutic vaccine Vacc-4x in combination with other
medicines toward a functional HIV cure. The company believes it has first
mover potential based on clinical results to date and early adoption of now
recognized clinical strategy. In December 2015, Bionor announced that the HIV
'Shock&Kill' trial REDUC with Vacc-4x and romidepsin successfully met its
primary endpoint by significantly reducing latent HIV reservoir and further
demonstrated control of viral load. Bionor is currently planning BIOSKILL, a
proof-of-concept Phase II trial, which may lead to a major value inflection
point and partnering opportunities. Bionor currently retains full ownership
rights to Vacc-4x, i.e., the upside potential from partnering or licensing
remains with the company. Bionor is based in Oslo, Norway, and also has
offices in Copenhagen, Denmark and New York, USA. Bionor is listed on Oslo
Børs (OSE:BIONOR). More information about Bionor is available
atwww.bionorpharma.com.

Bionor completes EGM
http://hugin.info/131219/R/1993718/734051.pdf
Bionor_EGM_Minutes_March2016
http://hugin.info/131219/R/1993718/734048.pdf

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Bionor Pharma ASA via Globenewswire

HUG#1993718

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.